2020
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research And Treatment 2020, 185: 215-227. PMID: 32939592, DOI: 10.1007/s10549-020-05931-9.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPN1 breast cancerRecurrence scoreChemotherapy useBreast cancerOverall survivalChemotherapy receiptPN1 patientsRS testingUse of RSNode-positive breast cancerOncotype DX recurrence scoreAdjuvant chemotherapy receiptLow genomic riskNode-positive diseaseAdjuvant treatment decisionsLow recurrence scoreShort-term outcomesMultivariate logistic regressionComprehensive cancer centerDX recurrence scoreOncotype DX testingChemotherapy omissionPT1-2N0Upfront surgery
2014
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Research And Treatment 2014, 145: 491-501. PMID: 24756187, DOI: 10.1007/s10549-014-2968-9.Peer-Reviewed Original ResearchConceptsNon-standard chemotherapyTrastuzumab-based therapyAdjuvant trastuzumab-based therapyOlder womenChemotherapy receiptHazard ratioBreast cancerHER2-positive breast cancerPattern of chemotherapyPropensity-weighted cohortsToxicity-related hospitalizationAdjusted hazard ratioTreatment-related toxicityMonths of chemotherapyShort-term outcomesMultivariable logistic regressionPopulation-based cohortPropensity score adjustmentAssociation of ageShort-term survivalComorbidity scoreOlder patientsTreatment toxicityWorse survivalHospital events